Business Wire

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

Jaa

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005695/en/

Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2. Presently, RAASi treatment is frequently discontinued due to the risk of hyperkalaemia (elevated blood potassium levels).

The DIAMOND study is designed to further support the use of Veltassa® to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients. It is a global, multicentre, double-blind, placebo-controlled trial aiming to study approximately 2,400 patients in over 400 sites. Eligible patients will have HF (with or without CKD) with either current hyperkalaemia at screening or a history of hyperkalaemia in the past year that led to a reduction or discontinuation of RAASi therapy. The primary endpoint of the study is the time to first occurrence of cardiovascular death or cardiovascular hospitalisation. Top-line results are expected in 2022.

Hyperkalaemia can cause life-threatening abnormal heart rhythms and even sudden death3. There are often no warning signs, meaning a person can unknowingly experience recurring spikes in potassium levels and be at risk of cardiac events. The risk of hyperkalaemia can be a barrier to initiating and maintaining HF and CKD patients on guideline-recommended therapies such as RAASi treatment1,2.

RAASi therapy has been shown to improve cardiovascular and renal outcomes and is proven to prolong survival and reduce hospitalisation. Its use is strongly recommended in clinical guidelines for the treatment of HF with reduced ejection fraction, and CKD1,2. Across the Veltassa® clinical trial program, over 99 percent of participants were also taking RAASi therapy. However, these therapies can increase blood potassium levels, which can lead to hyperkalaemia.

“Guidelines give their strongest recommendation to use RAASi therapy to improve mortality and morbidity in patients with heart failure and with kidney disease, but unfortunately they are often discontinued because they can cause hyperkalaemia,” said Professor Javed Butler, primary investigator of the DIAMOND study and chairman of the Department of Medicine, University of Mississippi Medical Center, US. “DIAMOND is a very important study that will help the medical community better understand the value of Veltassa® in treating hyperkalaemia and enabling patients to stay on these life-saving medicines.”

Additional details on the study are available on www.clinicaltrials.gov.

About Hyperkalaemia
Approximately 73 percent of advanced CKD and 40 percent of chronic HF patients may be at risk of elevated blood potassium levels4. Hyperkalaemia can cause abnormal heart rhythms and even sudden death3. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalaemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin-converting-enzyme (ACE) inhibitors as well as angiotensin II receptor/neprilysin inhibitors (ARNI).

About Veltassa ®
Veltassa® is a sodium-free potassium binder approved for the treatment of hyperkalaemia. Veltassa® should not replace emergency treatment for life-threatening hyperkalaemia. Made in powder form consisting of smooth, spherical beads, Veltassa® is mixed with water and taken once a day with food. Veltassa® is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.

Important Safety Information about Veltassa ® in the United States

Contraindications
Veltassa® is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa® or any of its components.

Worsening of Gastrointestinal Motility
Use of Veltassa® should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa® may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia
Veltassa® binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3 percent of patients treated with Veltassa®. Approximately 9 percent of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Doctors should monitor serum magnesium and consider magnesium supplementation in patients who develop low serum magnesium levels.

Adverse Reactions
The most common adverse reactions (incidence ≥2 percent) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3 percent of patients treated with Veltassa® and included edema of the lips.

For Veltassa®’s full Prescribing Information, please visit https://www.veltassa.com/pi.pdf.

Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com.

Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the development and commercialisation of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. Relypsa is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions that are often overlooked and undertreated. The company's first medicine, Veltassa® (patiromer) for oral suspension, was approved by the U.S. FDA in October 2015, making it the first approved medicine for the treatment of hyperkalaemia in more than 50 years. More information is available at www.relypsa.com.

References

1 Yancy C et al. American Heart Association. Guideline for the Management of Heart Failure. August 2017. Accessible via http://www.ksw-gtg.com/hfguidelines/pdfs/HFTreatmentHypertensionHFrEF.pdf.

2 Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200.

3 Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.

4 Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.

Contact information

Media Relations
Heide Hauer
Head of Corporate Communications
+41 58 851 80 87
media@viforpharma.com

Media Relations (US)
Albert Liao
Director of US Communications Relypsa
+1 650 421 9532
media@relypsa.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

FPT Software Joins IT Giants to Kick Off Airbus’s Skywise Certified Partner Program19.6.2019 15:00:00 EESTTiedote

FPT Software on Wednesday signed an agreement with Airbus to become one of the first Airbus’s Skywise certified partners to drive digital collaboration across the global aviation industry. Other four companies handpicked by Airbus to kick off this program include Accenture, CapGemini, IBM, and Sopra Steria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005409/en/ FPT Software and Airbus signed the agreement on the Skywise certified partner program at the sideline of the 53rd Paris Airshow on 19 June, 2019. (Photo: Business Wire) Airbus’s selection criteria of certified partners include companies with global presence, familiarity with Skywise technology, high-quality human resources, existing business with airlines, and existing business relationships with the European aircraft maker. According to Airbus, the Skywise certified partners will benefit from dedicated training and certification to help aviation players deve

Odaseva Appoints New Chief Legal Officer19.6.2019 15:00:00 EESTTiedote

Odaseva, the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced the appointment of Richard Zolezzi as the company’s new chief legal officer. In his role, Zolezzi will oversee the company’s worldwide legal affairs and support finance and human resources operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005095/en/ Richard Zolezzi named Odaseva's new chief legal officer (Photo: Business Wire) “Richard’s unique experience in supporting enterprise software companies through strategic expansion makes him the perfect fit to join Odaseva during this exciting time of growth,” said Sovan Bin, CEO and founder of Odaseva. “The need for overall data protection and compliance solutions has driven an increased demand for our solution, and we are thrilled to leverage Richard’s expertise.” Most recently, Richard led the Northe

New Survey Finds Fragmented Processes and System Silos Slowing Clinical Trials19.6.2019 14:19:00 EESTTiedote

There is an industrywide drive to streamline trial processes and systems for better study visibility and collaboration, according to the Veeva 2019 Unified Clinical Operations Survey, one of the largest-ever surveys of clinical operations professionals. New research from Veeva Systems (NYSE:VEEV) finds that all (100%) respondents surveyed report the need to improve information exchange among study partners. On average, they utilize at least three methods to share trial data and documents among sponsors, CROs, and sites, with email as the primary tool. Majorities say the move to streamline information exchange is driven by the need to reduce manual processes (71%), improve collaboration (66%), and increase visibility and oversight (64%) during trials. Nearly all sponsors and CROs (99%) say they also need to unify clinical applications for greater visibility (70%) and easier collaboration (61%). Many of the challenges in managing trials stem from siloed processes and systems that prevent

Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady19.6.2019 14:00:00 EESTTiedote

Virgin Voyages is upping the game for its top suites aboard the highly anticipated Scarlet Lady, with new offerings to ensure that Mega RockStars won’t have to worry about a thing during their voyage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005107/en/ Geri Horner of the Spice Girls testing out Virgin Voyages Mega Rockstar Suites in New Video (Photo: Business Wire) Geri Horner Test Drives RockStar Suites In celebration of the expanded offerings, the brand has today released exclusive video content of the suites, which features Virgin Group founder, Sir Richard Branson, and legendary British pop star, Geri Horner, of the hugely successful girl group, the Spice Girls. The video documents Horner test driving the Virgin Voyages ‘Gorgeous Suite,’ one of the ship’s most glamorous cabins, as a favor to her longtime friend, Branson. Following Horner’s journey through the suite, the footage chronicles her full RockStar ex

beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them19.6.2019 14:00:00 EESTTiedote

Despite three in four workers (75%) saying they are aware of gender pay gaps existing in their country, nearly one in five (19%) admit they are not aware. More U.S. workers (21%) are unaware of gender pay gaps than UK workers (17%); among age groups, Millennials (24%) are the most unaware, compared to 16% of Gen Zs and 11% of Baby Boomers. These findings are according to beqom’s The Gender Pay Gap: What Your Employees Really Think report, which assesses enterprise worker perception on progress made in the last year to improve the gender pay gap in the U.S. and UK and aims to uncover employee perceptions about pay and identify areas for improvement. When it comes to preventing or closing pay gaps, employees believe the U.S. significantly trails the UK, with nearly one-third of UK workers (32%) saying their employer has announced a commitment to solve the pay gap compared to 13% of U.S. workers. Additionally, more UK workers (18%) say their employer has adjusted salaries for female emplo

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 13:05:00 EESTTiedote

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme